Immunological and translational aspects of NK cell-based antitumor immunotherapies.
Front. Immunol. 7:492 (2016)
Natural killer (NK) cells play a pivotal role in the first line of defense against cancer. NK cells that are deficient in CD3 and a clonal T cell receptor (TCR) can be subdivided into two major subtypes, CD56dimCD16+ cytotoxic and CD56brightCD16− immunoregulatory NK cells. Cytotoxic NK cells not only directly kill tumor cells without previous stimulation by cytotoxic effector molecules, such as perforin and granzymes or via death receptor interactions, but also act as regulatory cells for the immune system by secreting cytokines and chemokines. The aim of this review is to highlight therapeutic strategies utilizing autologous and allogenic NK cells, combinations of NK cells with monoclonal antibodies to induce antibody-dependent cellular cytotoxicity, or immune checkpoint inhibitors. Additionally, we discuss the use of chimeric antigen receptor-engineered NK cells in cancer immunotherapy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
natural killer cell, immunotherapy, monoclonal antibody, antibody-dependent cellular cytotoxicity,
checkpoint inhibitors, chimeric antigen receptor; Natural-killer-cells; Chimeric Antigen Receptor; Phase-i Trial; Tumor-cells; T-cells; Colorectal-cancer; Multiple-myeloma; Nk-92 Cells; Adoptive Immunotherapy; Bispecific Antibodies
Keywords plus
Sprache
deutsch
Veröffentlichungsjahr
2016
Prepublished im Jahr
HGF-Berichtsjahr
2016
ISSN (print) / ISBN
1664-3224
e-ISSN
1664-3224
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 7,
Heft: ,
Seiten: ,
Artikelnummer: 492
Supplement: ,
Reihe
Verlag
Frontiers
Verlagsort
Lausanne
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Radiation Sciences
PSP-Element(e)
G-501300-001
Förderungen
Copyright
Erfassungsdatum
2016-11-29